Search

Your search keyword '"Giuseppe Viscardi"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Giuseppe Viscardi" Remove constraint Author: "Giuseppe Viscardi" Topic business.industry Remove constraint Topic: business.industry
47 results on '"Giuseppe Viscardi"'

Search Results

1. TERAVOLT: Thoracic Cancers International COVID-19 Collaboration

2. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology

3. Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma

4. Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy

5. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program

6. Chemotherapy-induced bowel ischemia: diagnostic imaging overview

7. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers

8. Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system

9. Circulating biomarkers in malignant pleural mesothelioma

10. 1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program

11. Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: Young oncologists' perspective

12. Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota

13. P40.08 Bone-Targeted Agents Improve Survival in High Bone Tumor Burden Advanced Non-Small-Cell-Lung Cancer Patients Treated With PD-(L)1 Inhibitors

14. 1830P Early deaths (ED) upon first-line immunecheckpoint inhibitors (ICI) alone or combined to other non-ICI drugs across solid cancers: A systematic review and meta-analysis

15. 1327P Impact of bone targeted agents (BTA) in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD(L)1 inhibitors (ICIs)

16. P-198 Prevalence of deleterious DPYD variants in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy

17. Abstract S12-03: Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies

18. 1329P Immune checkpoint inhibitors in advanced NSCLC patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers in a real world experience

19. 1335P Anti-tumour efficacy of cetuximab plus avelumab in NSCLC through induction of ADCC: Final data from CAVE-lung trial

20. Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study

21. Epsilon: A prognostic score for immunotherapy in advanced non-small-cell lung cancer: A validation cohort

22. 184P Bone-targeted agents (BTA) improve survival in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD-(L)-1 inhibitors (ICIs)

23. 196P A pivotal multicenter translational research project on malignant pleural mesothelioma (MPM): Preliminary results

24. P33.01 Circulating Extracellular Vesicles as Biomarkers for Immune-Checkpoint Inhibitors in Advanced NSCLC

25. 15P A pivotal multicenter translational research project on malignant pleural mesothelioma (MPM): Preliminary results

26. 1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts)

27. Abstract 4480: Circulating and tumor associated neutrophil subtypes correlate with hyperprogressive disease (HPD) upon immunecheckpoint inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC) patients (pts) and in vivo models

28. Efficacy and safety of immunotherapy in non-small cell lung cancer patients with poor performance status

29. Circulating and tumor-associated neutrophil subtypes discriminate hyperprogressive disease (HPD) from conventional progression (PD) upon immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (pts) and in vivo models

30. Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy

31. Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer

32. HGF/MET and the Immune System: Relevance for Cancer Immunotherapy

33. Clinical Approach: Recommendations for the Clinicians

34. Implication of the Hedgehog pathway in hepatocellular carcinoma

35. A novel ImmunoScore, based on clinical and blood biomarkers, as prognostic model for immunotherapy in NSCLC

36. Genomic profiling of non-oncogene-addicted aNSCLC using liquid biopsy. A single institution Italian experience

37. Proof of concept on the role of ex vivo lung cancer spheroids, cytokines expression and PBMCs profiling in monitoring disease history and response to treatments

38. Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature

41. Effect of MEK inhibition on PD-L1 and MCH-1 expression and on cytokines production profile in NSCLC cells and in human lymphocites

43. Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer

45. Role of the Hedgehog pathway in preventing occurrence of resistance to first, second, third generation EGFR-TKIs in first line therapy of NSCLC models with EGFR activating mutations

46. Efficacy of sequential treatment with first, second and third generation EGFR inhibitors and role of Hedgehog pathway in the acquisition of resistance in in vivo NSCLC models

Catalog

Books, media, physical & digital resources